AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12751941 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical technique (n=38)
Number of subjects: 73
Study 12751941 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive technique (n=35)
Number of subjects: 73
Study 10803456 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin, Lamotrigine, Tiagabine, Vigabatrin
Number of subjects: 0
Study 10803456 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate, Oxcarbazepine, Topiramate
Number of subjects: 0
Study 10803456 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 9552819 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond 2 (AB2) + Z‐100 composite
Number of subjects: 27
Study 9552819 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multipurpose Plus (SMPP) + Z‐100
Number of subjects: 27
Study 9552819 — intervention group
Group type: EXPERIMENTAL
Intervention: AB2 in conjunction with Bisfil 2B as liner and Z‐100
Number of subjects: 27
Study 9552819 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 8459990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v. 0, 4 and 8 h following chemotherapy)
Number of subjects: 2
Study 8459990 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (3 mg/kg i.v. followed by an infusion of 0.5 mg/kg/h for 8 h)
Number of subjects: 2
Study 8459990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 8 mg ondansetron 3 times daily for 5 days
Number of subjects: 2
Study 8459990 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (60 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 20 mg metoclopramide 3 times daily for 5 days
Number of subjects: 2
Study 8459990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) given orally twice daily
Number of subjects: 2
Study 3816928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone 1 g
Number of subjects: 8
Study 3816928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ceftriaxone 1 g
Number of subjects: 8
Study 31204873 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental biopsy group (6 anterior cores + 6 posterior cores)
Number of subjects: 340
Study 31204873 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy group (12 posterior cores)
Number of subjects: 340
Study 29684990 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) infusion
Number of subjects: 40
Study 29684990 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin infusion
Number of subjects: 40
Study 26880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 99
Study 26880105 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 99
Study 24492945 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 125
Study 24492945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 22614886 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiated before 3 months of age
Number of subjects: 90
Study 22614886 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 90
Study 20653225 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory occasion setter (screeching brakes)
Number of subjects: 0
Study 20653225 — intervention group
Group type: COMPARATOR
Intervention: Abstract auditory warning
Number of subjects: 0
Study 20653225 — intervention group
Group type: COMPARATOR
Intervention: Environmental auditory warning
Number of subjects: 0
Study 20653225 — intervention group
Group type: COMPARATOR
Intervention: Speech message
Number of subjects: 0
Study 20653225 — intervention group
Group type: COMPARATOR
Intervention: Visual display
Number of subjects: 0
Study 20653225 — intervention group
Group type: COMPARATOR
Intervention: No warning
Number of subjects: 0
Study 18796142 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Number of subjects: 97
Study 18796142 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 97
Study 18796142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 97
Study 16096242 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based brain injury rehabilitation service
Number of subjects: 1492
Study 16096242 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxonomy for goal classification
Number of subjects: 1492
Study 11836563 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR treatment for 6 months
Number of subjects: 1217
Study 11836563 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1217
Study 10626529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 61
Study 10626529 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 61
Study 8677154 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma antioxidant activity (AOA) during clinical treatment (induction of chemotherapy, surgery, radiotherapy, maintenance chemotherapy)
Number of subjects: 0
Study 8677154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin levels in children with malignancy
Number of subjects: 0
Study 2186259 — intervention group
Group type: EXPERIMENTAL
Intervention: Veramex 80 (80 mg non-retarded Verapamil)
Number of subjects: 18
Study 2186259 — intervention group
Group type: COMPARATOR
Intervention: Reference substance (80 mg non-retarded Verapamil)
Number of subjects: 18
Study 386125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g daily over eight weeks
Number of subjects: 15
Study 386125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31606042 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 0
Study 31606042 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 0
Study 31606042 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises alone
Number of subjects: 0
Study 28124478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (1200 mg daily)
Number of subjects: 657
Study 28124478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 657
Study 28124478 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 657
Study 25712967 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Number of subjects: 0
Study 25712967 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine
Number of subjects: 0
Study 25712967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose priming with mismatched pandemic influenza A(H5N1) vaccine
Number of subjects: 0
Study 23741965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 41
Study 23741965 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 41
Study 20192708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment with drospirenone 2 mg + estradiol emidrate 1 mg for 6 months
Number of subjects: 23
Study 20192708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study 18987654 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT wild type
Number of subjects: 601
Study 18987654 — intervention group
Group type: COMPARATOR
Intervention: TPMT low activity group (heterozygous and deficient)
Number of subjects: 601
Study 17854239 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time to all-cause treatment discontinuation
Number of subjects: 1627
Study 17854239 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers of trials (761 patients)
Number of subjects: 1627
Study 17854239 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater symptom improvement
Number of subjects: 1627
Study 15491558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (800 mcg)
Number of subjects: 200
Study 15491558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 mcg)
Number of subjects: 200
Study 12067152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 6
Study 12067152 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen (O2)
Number of subjects: 6
Study 9246650 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-management treatment group (n = 17)
Number of subjects: 48
Study 9246650 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition (n = 16)
Number of subjects: 48
Study 8297916 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 (60 or 120 mg Fe/d)
Number of subjects: 447
Study 8297916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 2436092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 150 mg nightly)
Number of subjects: 29
Study 2436092 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 29
Study 2688081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 1630
Study 2688081 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 1630
Study 2688081 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium retard 100 mg
Number of subjects: 1630
Study 2688081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1630
Study 31025412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 14
Study 31025412 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 14
Study 28809624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension brace (HB)
Number of subjects: 12
Study 28809624 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made semirigid orthosis (SO)
Number of subjects: 12
Study 28809624 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made rigid orthosis (RO)
Number of subjects: 12
Study 28809624 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 Health Survey
Number of subjects: 12
Study 25323621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI)
Number of subjects: 542
Study 25323621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 25323621 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms scale
Number of subjects: 542
Study 23229461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 22
Study 23229461 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 22
Study 21537338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training on a treadmill with body weight support (group A)
Number of subjects: 30
Study 21537338 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training and physiotherapy (group B)
Number of subjects: 30
Study 19351876 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan treatment for 90 days
Number of subjects: 3194
Study 17168667 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol® evening primrose oil (EPO)
Number of subjects: 1207
Study 15526247 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB, irbesartan
Number of subjects: 68
Study 15526247 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor, captopril
Number of subjects: 68
Study 15526247 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy controls)
Number of subjects: 68
Study 10902932 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged decompression while breathing 100% oxygen (SD100) with 15 min of ground-level preoxygenation and an additional 60 or 120 min of SD100 at altitudes between 8,000 ft and 18,000 ft.
Number of subjects: 30
Study 10902932 — intervention group
Group type: COMPARATOR
Intervention: Control exposures with 75- or 135-min ground-level preoxygenation.
Number of subjects: 30
Study 9315176 — intervention group
Group type: EXPERIMENTAL
Intervention: Funisocentesis
Number of subjects: 41
Study 8366821 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (250 mg/Kg on the first and seventh day after admission)
Number of subjects: 40
Study 8366821 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 40
Study 3771829 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reminder for high scorers on the TEQ
Number of subjects: 0
Study 3771829 — intervention group
Group type: EXPERIMENTAL
Intervention: Two reminders for low scorers on the TEQ
Number of subjects: 0
Study 3771829 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 0
Study 3771829 — intervention group
Group type: COMPARATOR
Intervention: Telephone reminders
Number of subjects: 0
Study 30822311 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sine wave single-frequency stimulation (40 Hz) for 30 minutes, five days per week, over five weeks, concomitant with usual care.
Number of subjects: 50
Study 30822311 — intervention group
Group type: COMPARATOR
Intervention: Random and intermittent complex wave gamma-range vibrotactile stimulation for 30 minutes, five days per week, over five weeks, concomitant with usual care.
Number of subjects: 50
Study 28865940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) 24 IU
Number of subjects: 22
Study 28865940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26537570 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular telephone calls every 2 weeks and weekly text messages for 6 months (intervention group)
Number of subjects: 0
Study 26537570 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23010790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (amoxicillin with clavulanic acid) for 5 days
Number of subjects: 0
Study 23010790 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 0
Study 20086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine receptor 1 antagonist BX 471
Number of subjects: 34
Study 20086017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18159115 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body periodic acceleration (2-3 Hz, +/-2.2 m/s2 for 45 min)
Number of subjects: 26
Study 18159115 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 26
Study 16820546 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice per day)
Number of subjects: 1025
Study 16820546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice per day)
Number of subjects: 1025
Study 16820546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1025
Study 16820546 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1025
Study 16820546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 1025
Study 15156789 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of acceleration for leftward movements
Number of subjects: 1
Study 15156789 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in unilateral neglect after 14 months
Number of subjects: 1
Study 15156789 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other patients
Number of subjects: 1
Study 10782754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 60
Study 10782754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7745771 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue‐type plasminogen activator (rt‐PA) plus IV heparin
Number of subjects: 40021
Study 7745771 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase plus either subcutaneous or intravenous (IV) heparin
Number of subjects: 40021
Study 7745771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined streptokinase and rt‐PA plus IV heparin
Number of subjects: 40021
Study 7745771 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in the United States
Number of subjects: 40021
Study 2203214 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (medical gymnastics)
Number of subjects: 0
Study 2203214 — intervention group
Group type: COMPARATOR
Intervention: Perineal electrical stimulation
Number of subjects: 0
Study 7019293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinkel injection therapy (RIT)
Number of subjects: 155
Study 7019293 — intervention group
Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 155
Study 30085324 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (active treatment)
Number of subjects: 629
Study 30085324 — intervention group
Group type: EXPERIMENTAL
Intervention: HiSCR responders
Number of subjects: 629
Study 30085324 — intervention group
Group type: COMPARATOR
Intervention: HiSCR non-responders
Number of subjects: 629
Study 26970434 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based collaborative care intervention
Number of subjects: 261
Study 26970434 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 261
Study 24905929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - GaAlAs diode laser [780 nm, 30 mW continuous wave (CW), 0.785 cm(2), 38.2 mW/cm(2)], applied for 90 sec per point, 5 times per week for 2 weeks, followed by 10 treatments every other day for 3 weeks (total of 20 treatments)
Number of subjects: 79
Study 24905929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) laser treatment
Number of subjects: 79
Study 22264667 — intervention group
Group type: EXPERIMENTAL
Intervention: First condom use period (FCs)
Number of subjects: 170
Study 22264667 — intervention group
Group type: EXPERIMENTAL
Intervention: Second condom use period (FCs)
Number of subjects: 170
Study 22264667 — intervention group
Group type: EXPERIMENTAL
Intervention: Third condom use period (FCs)
Number of subjects: 170
Study 22264667 — intervention group
Group type: EXPERIMENTAL
Intervention: Final use of FC in the last period
Number of subjects: 170
Study 20197530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 3350
Study 20197530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3350
Study 18793528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet administered with the first major meal after dialysis
Number of subjects: 673
Study 18793528 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet administered with food during the dialysis session
Number of subjects: 673
Study 15921057 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Method Learning (CML) intervention group
Number of subjects: 255
Study 15921057 — intervention group
Group type: COMPARATOR
Intervention: Primary care control group
Number of subjects: 255
Study 15921057 — intervention group
Group type: COMPARATOR
Intervention: External specialist control group
Number of subjects: 255
Study 15921057 — intervention group
Group type: EXPERIMENTAL
Intervention: CML intervention group
Number of subjects: 255
Study 15921057 — intervention group
Group type: COMPARATOR
Intervention: Specialist clinic group
Number of subjects: 255
Study 11797179 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine-zidovudine (150 mg/300 mg) combination tablet and one 300-mg abacavir tablet administered twice daily
Number of subjects: 108
Study 9830895 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically controlled beds
Number of subjects: 782
Study 9830895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as standard care without electric beds)
Number of subjects: 782
Study 8129119 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 50 micrograms
Number of subjects: 30
Study 8129119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 5 micrograms.ml‐1 (dose 40 mg)
Number of subjects: 30
Study 8129119 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 2628746 — intervention group
Group type: EXPERIMENTAL
Intervention: meat vegetable dinner fortified with iron‐2‐sulfate (3 mg iron per 100 kcal)
Number of subjects: 73
Study 2628746 — intervention group
Group type: EXPERIMENTAL
Intervention: milk based rice cereal (MBRC) fortified with iron‐3‐pyrophosphate (3 mg iron per 100 kcal)
Number of subjects: 73
Study 2628746 — intervention group
Group type: COMPARATOR
Intervention: non iron fortified vegetable potato dinner
Number of subjects: 73
Study 9890789 — intervention group
Group type: EXPERIMENTAL
Intervention: sulthiame
Number of subjects: 22
Study 9890789 — intervention group
Group type: COMPARATOR
Intervention: diphenylhydantoin
Number of subjects: 22
Study 31000477 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (40 mg/kg) intravenously every 3 weeks for up to 24 weeks during analytic interruption of ART
Number of subjects: 19
Study 31000477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) intravenously every 3 weeks for up to 24 weeks during analytic interruption of ART
Number of subjects: 19
Study 29125783 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge intervention
Number of subjects: 201
Study 29125783 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment intervention
Number of subjects: 201
Study 26487008 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (1.7 g/min)
Number of subjects: 14
Study 26487008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose ingestion (1.7 g/min)
Number of subjects: 14
Study 26487008 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion (control)
Number of subjects: 14
Study 23553291 — intervention group
Group type: COMPARATOR
Intervention: Balloon kyphoplasty
Number of subjects: 100
Study 23553291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral body stenting
Number of subjects: 100
Study 22230405 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil
Number of subjects: 240
Study 22230405 — intervention group
Group type: COMPARATOR
Intervention: Wild-type (A118A) patients
Number of subjects: 240
Study 22230405 — intervention group
Group type: EXPERIMENTAL
Intervention: A118G carriers
Number of subjects: 240